Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | TP53 | P04637 | 3/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.47 |
| ▸ | TSPO | P30536 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL769874 | 0.85 | MAPT (0.51) | MAPTTP53GSK3BLMNAHPGD | |
| SCHEMBL770026 | 0.79 | CNR2 (0.53) | MAPTTP53LMNAHPGDSMN1; SMN2 | |
| SCHEMBL15201290 | 0.78 | FGFR1 (0.59) | MAPTTP53GSK3BLMNAHPGD | |
| SCHEMBL769873 | 0.76 | MAPT (0.54) | MAPTTP53GSK3BLMNAHPGD | |
| SCHEMBL769872 | 0.75 | MAPT (0.56) | MAPTTP53GSK3BLMNAHPGD | |
| SCHEMBL769761 | 0.75 | NPC1 (0.64) | MAPTTP53LMNAHPGDSMN1; SMN2 | |
| SCHEMBL15201869 | 0.73 | ALDH1A1 (0.57) | MAPTTP53GSK3BLMNAHPGD | |
| SCHEMBL15201870 | 0.73 | ALDH1A1 (0.57) | MAPTTP53GSK3BLMNAHPGD | |
| SCHEMBL1408358 | 0.69 | KDR (0.69) | MAPTTP53GSK3BLMNAHPGD | |
| SCHEMBL19781278 | 0.69 | KDR (0.58) | MAPTTP53GSK3BHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629170-B2 | Anti-viral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. (US) | 2014-01-14 | — | — | US | claimed |
| EP-1988776-B1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES INC (US) | 2012-08-08 | — | — | EP | claimed |
| US-20110172281-A1 | Anti-Viral Drugs for Treatment of Arenavirus Infection | SIGA TECHNOLOGIES INC. (US) | 2011-07-14 | — | — | US | claimed |
| US-7977365-B2 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. (US) | 2011-07-12 | — | — | US | claimed |
| EP-2291184-A2 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | Siga Technologies, Inc. (US) | 2011-03-09 | — | — | EP | claimed |
| US-7872037-B2 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. (US) | 2011-01-18 | — | — | US | claimed |
| WO-2010036399-A2 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES, INC. (US) | 2010-04-01 | — | — | WO | claimed |
| US-20080300265-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVRUS INFECTION | SIGA TECHNOLOGIES INC. (US) | 2008-12-04 | — | — | US | claimed |
| EP-1988776-A2 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES, INC. (US) | 2008-11-12 | — | — | EP | claimed |
| US-20070254934-A1 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. | 2007-11-01 | — | — | US | claimed |
| WO-2007103111-A2 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES, INC. (US) | 2007-09-13 | — | — | WO | claimed |
| US-8871746-B2 | Antiviral drugs for treatment of arenavirus infection | Kineta Four, LLC (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871746-B2 | Antiviral drugs for treatment of arenavirus infection | Kineta Four, LLC (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871746-B2 | Antiviral drugs for treatment of arenavirus infection | Kineta Four, LLC (US) | 2014-10-28 | — | — | US | disclosed |
| US-8629170-B2 | Anti-viral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. (US) | 2014-01-14 | — | — | US | disclosed |
| US-20080300265-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVRUS INFECTION | SIGA TECHNOLOGIES INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080300265-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVRUS INFECTION | SIGA TECHNOLOGIES INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080300265-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVRUS INFECTION | SIGA TECHNOLOGIES INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-20070254934-A1 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. | 2007-11-01 | — | — | US | disclosed |
| US-20070254934-A1 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172281-A1 | Anti-Viral Drugs for Treatment of Arenavirus Infection | GK, GALK1, KLK7 | MAPT 923/4885TP53 2958/4885GSK3B 1840/4885 |
| US-20070254934-A1 | Antiviral drugs for treatment of arenavirus infection | GK, GALK1, GZMB | MAPT 1022/4885TP53 2978/4885GSK3B 1743/4885 |
| US-20080300265-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVRUS INFECTION | GK, MAVS, ZC3HAV1 | MAPT 1158/4885TP53 3110/4885GSK3B 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.